ProMIS NeurosciencesPMN
Recorded

ProMIS Neurosciences UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Aidan BrackenDirector

Morning, everyone. My name is Aidan Bracken. I am a Director on the UBS Biopharmaceuticals team. I wanted to say a quick thank you to all the attendees and presenters at our inaugural biopharma conference. With that, happy to introduce Neil Warma, the CEO of ProMIS Neurosciences.

Neil WarmaCEO

Neil. Yeah. Thanks, Aidan. Aidan, sorry.

Neil WarmaCEO

I appreciate it. And thanks for the invitation to the conference. You guys have a great turnout. Thanks, folks, for joining this morning. Yeah, I will run through a few slides and then maybe take a few questions at the end, if that makes sense, and walk through. But thanks for joining this morning. ProMIS Neurosciences, just to remind everybody that we are a public company, so please review the SEC filings for a clear understanding of our operations. Just as a high-level overview of ProMIS, as I said, we are a publicly listed company. PMN is the ticker. We are based in Cambridge, in Boston, Massachusetts. The name ProMIS, which may not be obvious, and the promise of novel therapeutics, but also based on our technology platform, protein misfolding. So we have the ability to design very selective, highly selective antibodies directed against misfolded proteins.

Neil WarmaCEO

The name of our technology platform, EpiSelect, has allowed us over the years to develop some very interesting, very selective antibodies. We are, and I will spend a few minutes, obviously, on the phase I-B study, which reads out in Q1 of 2027, so just a few months away. And we have a next-generation anti-amyloid monoclonal antibody for Alzheimer's disease. So I will spend a few minutes on that in a few minutes. We are reasonably well-financed, cash through to the end of next year, end of 2027. We did a financing, well, a few months ago now, earlier this year, where we brought in up to $175 million with some of the best institutional investors, with Janus and Ally Bridge leading. We had Wellington, Deep Track, Trails Edge, so a really terrific syndicate. So, nicely financed. I will spend most of the presentation on Alzheimer's disease.

Neil WarmaCEO

As I said, that is where our lead asset is focused. The data is coming shortly, and obviously a huge unmet medical need. This slide kind of speaks to itself, the prevalence of Alzheimer's in the U.S. and globally, which I think everybody probably in this audience and listening in has been impacted in some way, directly or indirectly, by Alzheimer's disease. As you likely know, there are a couple of products on the market to treat early-stage Alzheimer's disease, both donanemab from Lilly and lecanemab from Eisai and Biogen. And the chart shows really the benefit-risk profile, and I will talk a fair amount about benefit-risk. That is how we assess drugs after the FDA, EMAs, the regulatory authorities really evaluate drugs according to benefit-risk portfolio, as do prescribing physicians and even patients. And for the drugs in the market, the benefit-risk profile is modest.

Neil WarmaCEO

I have to admit, the efficacy is relatively modest, the benefit to patients. The risk is quite significant. We will come back to the side effect issues with drugs that are on the market to treat Alzheimer's disease, and you will hear this term ARIA, which is the side effect associated with drugs that target plaque. I will come back to that key message in a minute. Drugs that target plaque and clear plaque are associated with ARIA, and this is either swelling or bleeding on the brain. The risk is pretty significant with these drugs. The benefit is modest, but they have the kind of commercial validation, if you will. These drugs are still generating significant revenue, or anticipating kind of $2 billion-$3 billion in peak sales. The market is there. The unmet medical need is certainly there as well.

Neil WarmaCEO

But if you look at the percentage of the early Alzheimer's market that these drugs are going after, MCI, mild cognitive impairment due to Alzheimer's disease, given the challenging benefit-risk profile, they are capturing roughly 5% of that MCI population. The reasons for that, if there is a laser on this, the reasons for that on the right side are due to this ARIA, swelling and bleeding on the brain. The side effect issues, overall side effect issues, even infusion reactions, MRI, and that is part of the issue. Not only do you get swelling and bleeding on the brain, the MRIs that are required to monitor these patients consistently, so six MRIs are required over the first year of treatment for these patients. The issues are significant, which prevents the uptake. The need for new medicines obviously is key. Excuse me while I sip my water.

Neil WarmaCEO

I am coming off a cold. Touching on our program, PMN310, that is the name of our lead candidate, right now in a phase Ib study targeting the MCI early Alzheimer's patient population. Just looking at the science, I will come back to the idea or the challenge of really looking at amyloid-beta protein as a target, and it is a validated target, but where in the There are multiple species of A-beta protein, and where do you target or how can you selectively target the bad ones versus the good ones? Our target for our antibody are the upstream, the toxic oligomers. These are misfolded forms of these toxic oligomers that, as they progress downstream, form plaque and trigger tau phosphorylation. We want to go upstream and capture the toxic oligomer population, which is And again, if you do that, you prevent the downstream damaging effects.

Neil WarmaCEO

The oligomers are known to be highly synaptotoxic, so they damage the neurons, specifically the synapses. They also trigger tau phosphorylation, so the tangles that are associated with tau. We want to hit them upstream before they go downstream to cause their damage. Interestingly, an important distinction that we have been talking about for the past few weeks is the backbone that we use for our antibody. Because many as you know from immunology class, you can pick and choose your backbone from IgG1, two, three, and four. We, on purpose, selected an IgG1 because it is important, we believe, not only to bind the, so neutralize the toxic oligomers, but clear them, remove them from circulation in the CSF. I will show that in just a second as well.

Neil WarmaCEO

The challenge really in going after A-beta protein is, as I mentioned, there are multiple different species of A-beta protein. This pyramid kind of depicts the three most prevalent, but also the relative concentrations of each. The toxic oligomers that we're going after, again, this is the same target that lecanemab, the drug in the market by Eisai, was designed to target. The challenge is designing an antibody that selectively targets only the pathogenic form and does not target the rest. But the conventional way of making antibodies, it's almost impossible, if not impossible, to not cross-react with all forms of A-beta protein. I'll come back to this in just a second, but there's a linear epitope in the conventional way of making antibodies that's conserved across species. The drugs on the market, the drugs in development, all target all forms of amyloid-beta.

Neil WarmaCEO

Some more selectively. Lecanemab was designed to go selectively after the oligomers, but at the end of the day, they bind plaque, and they come with ARIA, and they also bind monomers as well. The challenge is that we see, again, the field has shifted away from plaque over the past number of years. In the past, as you know, you can image plaque, you can see plaque. Therefore, the thinking decades ago was if we can remove plaque, that will prevent further cognitive decline. Now we know that's not the case. Plaque is not really that important nor that relevant for preventing cognitive decline. Now we know that if you target and clear plaque, not only is it not relevant, but you also get ARIA, this bleeding and swelling on the brain.

Neil WarmaCEO

Again, that's the bigger challenge is, well then, how do you avoid plaque, and how do you avoid even the monomers? The monomers are actually a beneficial form of A-beta protein. They have a biological function, so you don't want to target those. But then, how do you design something that avoids monomers and avoids plaque and hits what we now believe to be the true driver of toxicity and cognitive decline? How can you do that? That's when it comes to our technology platform, and not to get too deep into our EpiSelect platform. But as I mentioned previously, the conventional way of designing antibodies is more a brute force screen, looking at antibodies that try to be more selective to the target of choice. But with a linear epitope that's conserved, you can't avoid cross-reacting with all forms.

Neil WarmaCEO

What we do at ProMIS is, again, it's all based on protein misfolding, but we have a, it's really a computational or an algorithmic way of predicting how proteins are going to misfold. So there's this linear component, but there's also this three-dimensional folding of the protein that's very important to the design of our antibodies. So we get this conformational three-dimensional epitope against which we design an antibody that binds that binding domain, which only exists on, in our case here, the toxic oligomers. That bind three-dimensional does not exist on monomers, and it's buried in plaque. So we've tried and tested to say, "Are we able to bind plaque?" Not that we want to, but can we demonstrate that we cannot, that we do not bind plaque? We've done multiple studies. So there's a fundamental different way.

Neil WarmaCEO

I mean, we have a chief physics officer in our company that really drives the algorithmic approach to designing antibodies that are highly selective. As we mentioned here, it's kind of the fancy image to show the three-dimensional conformation, and then again, with that IgG1 backbone, we get neutralization of the oligomer and clearance. The IgG1 provides that effector function, which recruits the immune cells, which recruits the microglia, which come in and degrade the oligomer species, because you don't want them sitting around in CSF. Even if they're bound or neutralized, you want them out of the way. As I mentioned, we looked at just briefly kind of side-by-side tests just to demonstrate, are we differentiated to all the other antibodies out there?

Neil WarmaCEO

Because we got a lot of questions from folks saying, "Other companies have come and have suggested they have a selective antibody for oligomers." But at the end of the day, they all bind plaque, they all come with ARIA. ProMIS comes along and says, "No, no, we're the ones that have that." And they're like, "Yeah, okay, tell us how you can be different than the others." And it's like, "Well, this is how we make designer antibodies, which is fundamentally different." Then we've done side-by-side tests, and this is just one where we looked at PMN310, our antibody, against all the others. The one from Acumen, but donanemab, lecanemab, aducanumab, and showed that the green lines are, the green fluorescence are the presence of plaque in Alzheimer's sections, and the purple show where the antibodies actually bind that plaque.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day